Commentary

Podcast

Pharmacy Focus: Student Edition - Accelerating Success: Western University of Health Sciences' 3.5-Year Program

Tune in to this episode of Pharmacy Focus: Student Edition to discover how innovative programs like Western University's 3.5-year pharmacy program are shaping the future of pharmacy education.

In this episode, we explore an innovative approach to pharmacy education with Sunil Prabhu, BPharm, PhD, dean and professor at the College of Pharmacy at the Western University of Health Sciences. Prabhu sheds light on Western University of Health Sciences' unique 3.5-year pharmacy program, uncovering the benefits it offers students, how it streamlined curriculum, the application process, and the potential to meet the evolving needs of the pharmacy profession.

Key Takeaways:

  1. Western University's 3.5-year pharmacy program offers students an accelerated pathway to a rewarding pharmacy career.
  2. The program's curriculum is meticulously designed to meet all necessary requirements while streamlining the educational process.
  3. Students interested in the program can gain valuable insights into the application process.
  4. This innovative approach to pharmacy education could help address some staffing needs more rapidly and adapt to the evolving demands of the profession.
Related Videos
Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen | stock.adobe.com
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
Pharmacists working in a pharmacy -- Image credit: Drazen | stock.adobe.com
Image Credit: © Krakenimages.com - stock.adobe.com
Young female pharmacist working in her large pharmacy. Placing medications, taking inventory. Lifestyle - Image credit: lubero | stock.adobe.com
WCLC, lung cancer, NSCLC
MARIPOSA Study: Long-Term Outcomes and Next Steps for Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC
Pharmacist helping patient -- Image credit: Clayton D/peopleimages.com | stock.adobe.com
The EMPOWER-Lung 1 Trial: Five-Year Outcomes of Cemiplimab Monotherapy in Advanced NSCLC